ATE210648T1 - 3,4-substituierte pyrazole zur behandlung von entzündungen - Google Patents

3,4-substituierte pyrazole zur behandlung von entzündungen

Info

Publication number
ATE210648T1
ATE210648T1 AT95927154T AT95927154T ATE210648T1 AT E210648 T1 ATE210648 T1 AT E210648T1 AT 95927154 T AT95927154 T AT 95927154T AT 95927154 T AT95927154 T AT 95927154T AT E210648 T1 ATE210648 T1 AT E210648T1
Authority
AT
Austria
Prior art keywords
alkyl
inflammation
arylaminocarbonyl
haloalkyl
amino
Prior art date
Application number
AT95927154T
Other languages
English (en)
Inventor
Len F Lee
Thomas D Penning
Steven W Kramer
John J Talley
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23064457&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE210648(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Searle & Co filed Critical Searle & Co
Application granted granted Critical
Publication of ATE210648T1 publication Critical patent/ATE210648T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT95927154T 1994-07-21 1995-07-20 3,4-substituierte pyrazole zur behandlung von entzündungen ATE210648T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/278,297 US5486534A (en) 1994-07-21 1994-07-21 3,4-substituted pyrazoles for the treatment of inflammation
PCT/US1995/008788 WO1996003385A1 (en) 1994-07-21 1995-07-20 3,4-substituted pyrazoles for the treatment of inflammation

Publications (1)

Publication Number Publication Date
ATE210648T1 true ATE210648T1 (de) 2001-12-15

Family

ID=23064457

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95927154T ATE210648T1 (de) 1994-07-21 1995-07-20 3,4-substituierte pyrazole zur behandlung von entzündungen

Country Status (11)

Country Link
US (4) US5486534A (de)
EP (2) EP1127878A1 (de)
JP (1) JP3490716B2 (de)
AT (1) ATE210648T1 (de)
AU (1) AU3126795A (de)
CA (1) CA2195123A1 (de)
DE (1) DE69524600T2 (de)
DK (1) DK0772597T3 (de)
ES (1) ES2169760T3 (de)
PT (1) PT772597E (de)
WO (1) WO1996003385A1 (de)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2223154A1 (en) * 1995-06-02 1996-12-05 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
ATE301457T1 (de) * 1995-06-12 2005-08-15 Searle & Co Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor
US6342510B1 (en) * 1995-06-12 2002-01-29 G. D. Searle & Co. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitors and a leukotriene B4 receptor antagonist
WO1997029776A1 (en) * 1996-02-13 1997-08-21 G.D. Searle & Co. Combinations having immunosuppressive effects, containing cyclooxygenase-2-inhibitors and 5-lipoxygenase inhibitors
AU1952597A (en) 1996-02-13 1997-09-02 G.D. Searle & Co. Combinations, having immunosuppressive effects, containing cyclooxygenase-2 inhibitor and a leukotriene a4 hydrolase inhibitor
ES2243978T3 (es) 1996-02-13 2005-12-01 G.D. SEARLE & CO. Composiciones que comprenden un inhibidor de la ciclooxigenasa-2 y un antagonista del receptor de leucotrieno b4.
US5908858A (en) * 1996-04-05 1999-06-01 Sankyo Company, Limited 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
GEP20032998B (en) 1996-04-12 2003-06-25 Searle & Co Substituted Benzenesulfonamide Derivatives as Prodrugs of Cox-2 Inhibitors
ATE271385T1 (de) 1996-10-15 2004-08-15 Searle Llc Verwendung von cyclooxygenase-2 inhibitoren zur behandlung und verbeugung von neoplasia
US5985930A (en) * 1996-11-21 1999-11-16 Pasinetti; Giulio M. Treatment of neurodegenerative conditions with nimesulide
ID18983A (id) * 1996-12-04 1998-05-28 Lilly Co Eli Pirazola sebagai inhibitor sekresi fosfolipase a2 non-pankreas pada manusia
BR9807920A (pt) * 1997-04-03 2000-02-22 Searle & Co Processos para tratamento de uma demência em um sujeito e para prevenção de uma demência
US5932576A (en) * 1997-05-22 1999-08-03 G. D. Searle & Company 3(5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
US6514977B1 (en) * 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
NZ501112A (en) * 1997-05-22 2002-10-25 G Substituted pyrazoles as p38 kinase inhibitors
US6087381A (en) * 1997-05-22 2000-07-11 G. D. Searle & Company Pyrazole derivatives as p38 kinase inhibitors
US20020156104A1 (en) * 1997-06-13 2002-10-24 Jerry L. Adams Novel pyrazole and pyrazoline substituted compounds
US6525053B1 (en) 1997-08-22 2003-02-25 Abbott Laboratories Prostaglandin endoperoxide H synthase biosynthesis inhibitors
US6307047B1 (en) * 1997-08-22 2001-10-23 Abbott Laboratories Prostaglandin endoperoxide H synthase biosynthesis inhibitors
AUPP042397A0 (en) * 1997-11-18 1997-12-11 Fujisawa Pharmaceutical Co., Ltd. 5-arylpyrazole compounds
US6025353A (en) * 1997-11-19 2000-02-15 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
US6887893B1 (en) * 1997-12-24 2005-05-03 Sankyo Company, Limited Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia
US6294558B1 (en) * 1999-05-31 2001-09-25 Pfizer Inc. Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
US6727238B2 (en) 1998-06-11 2004-04-27 Pfizer Inc. Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
WO2000018741A2 (en) * 1998-09-30 2000-04-06 Fujisawa Pharmaceutical Co., Ltd. Pyrazole compounds as cox-2 inhibitors
US6649645B1 (en) * 1998-12-23 2003-11-18 Pharmacia Corporation Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
KR100711538B1 (ko) * 1998-12-25 2007-04-27 아스카 세이야쿠 가부시키가이샤 아미노피라졸 유도체
CN1281604C (zh) * 1999-06-03 2006-10-25 帝国脏器制药株式会社 取代吡唑化合物
DK1104758T3 (da) * 1999-12-03 2003-10-20 Pfizer Prod Inc Acetylenderivativer som anti-inflammatoriske/analgesiske lægemidler
CO5261556A1 (es) * 1999-12-08 2003-03-31 Pharmacia Corp Composiciones inhibidoras de ciclooxigenasa-2 que tiene rapido acceso de efecto terapeutico
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
EP1299123A2 (de) * 2000-07-13 2003-04-09 Pharmacia Corporation Verwendung von cox-2 hemmern zur behandlung und vorbeugung von cox-2-abhängigen augenkrankheiten
NZ524252A (en) 2000-07-20 2004-03-26 Lauras As Cox-2 inhibitors for treating HIV and AIDS
JP2004531456A (ja) * 2000-09-06 2004-10-14 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 置換ピラゾールを用いてアレルギーを治療する方法
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
JP2004522754A (ja) * 2001-02-02 2004-07-29 ファルマシア・コーポレーション 月経困難症の治療および予防のための組み合わせ治療としてシクロオキシゲナーゼ‐２阻害剤および性ステロイドを使用する方法
PE20021017A1 (es) 2001-04-03 2002-11-24 Pharmacia Corp Composicion parenteral reconstituible
US20030105144A1 (en) 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
US6673818B2 (en) * 2001-04-20 2004-01-06 Pharmacia Corporation Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
EP2048142A3 (de) 2001-04-26 2009-04-22 Eisai R&D Management Co., Ltd. Stickstoffhaltige, kondensierte zyklische Verbindung mit Pyrazolyl-Gruppe als substituierende Gruppe und pharmazeutische Zusammensetzung daraus
US7076539B2 (en) * 2001-07-30 2006-07-11 Hewlett-Packard Development Company, L.P. Network connectivity establishment at user log-in
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
CZ20022642A3 (cs) * 2001-08-27 2003-09-17 Pfizer Products Inc. Způsob výroby dialkylpyridylboranů
YU30504A (sh) 2001-09-25 2006-08-17 Pharmacia Corporation Postupak za dobijanje supstituisanih pirazola
US7057049B2 (en) 2001-09-25 2006-06-06 Pharmacia Corporation Process for making substituted pyrazoles
JP4399265B2 (ja) 2001-12-21 2010-01-13 ヴァーナリス（ケンブリッジ）リミテッド ３，４−ジアリールピラゾール、および癌の治療におけるそれらの使用
US7842693B2 (en) * 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
US7589199B2 (en) * 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
DK1531822T3 (da) * 2002-06-12 2009-12-07 Chemocentryx Inc 1-aryl-4-substituerede piperazin derivater til anvendelse som CCR1 antagonister til behandlingen af inflammation og immunforstyrrelser
US20050256130A1 (en) * 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
KR100478467B1 (ko) * 2002-06-24 2005-03-23 씨제이 주식회사 피라졸-3-온 유도체, 그 제조방법 및 약제학적 조성물
JP2005535642A (ja) * 2002-06-28 2005-11-24 ニトロメッド インコーポレーティッド オキシムおよび／またはヒドラゾンを含有するニトロソ化および／またはニトロシル化シクロオキシゲナーゼ−２選択的阻害剤、組成物、および使用方法
WO2004009560A1 (en) * 2002-07-22 2004-01-29 Orchid Chemicals & Pharmaceuticals Ltd Novel bio-active molecules
PT1572173E (pt) 2002-12-13 2010-05-10 Warner Lambert Co Ligando alfa-2-delta para tratar sintomas do tracto urinário inferior
GB0229618D0 (en) * 2002-12-19 2003-01-22 Cancer Rec Tech Ltd Pyrazole compounds
CL2004000234A1 (es) * 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
EP1597234B1 (de) * 2003-02-27 2008-10-08 Smithkline Beecham Corporation Neue verbindungen
JP4736043B2 (ja) * 2003-03-14 2011-07-27 小野薬品工業株式会社 含窒素複素環誘導体およびそれらを有効成分とする薬剤
PT1622630E (pt) * 2003-05-07 2012-10-11 Osteologix As Combinações de estrôncio para a profilaxia/tratamento de patologias da cartilagem e/ou do osso
PT1534305E (pt) * 2003-05-07 2007-02-28 Osteologix As Tratamento de afecções cartilagineas / osseas com sais de estroncio hidrosoluveis
CN103484486B (zh) * 2003-07-02 2018-04-24 维莱尼姆公司 葡聚糖酶，编码它们的核酸以及制备和使用它们的方法
WO2005037797A1 (en) * 2003-10-21 2005-04-28 Pharmacia Corporation Substituted pyrazole urea compounds for the treatment of inflammation
WO2005044227A1 (en) * 2003-11-05 2005-05-19 Glenmark Pharmaceuticals Limited Topical pharmaceutical compositions
US20050100594A1 (en) * 2003-11-12 2005-05-12 Nilendu Sen Pharmaceutical formulation containing muscle relaxant and COX-II inhibitor
EP1708718A1 (de) 2004-01-22 2006-10-11 Pfizer Limited Triazol-derivate zur hemmung der vasopressing-antagonistischen aktivität
US7435831B2 (en) * 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
AU2005219438B2 (en) * 2004-03-03 2011-02-17 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
AU2005283326B2 (en) * 2004-09-13 2011-07-21 Ono Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient
JP2008515992A (ja) 2004-10-13 2008-05-15 ピーティーシー セラピューティクス，インコーポレーテッド 体細胞変異に起因する疾患の阻止／治療用医薬を製造するための規定化合物の使用
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
NL2000351C2 (nl) 2005-12-22 2007-09-11 Pfizer Prod Inc Estrogeen-modulatoren.
US7863446B2 (en) * 2006-01-19 2011-01-04 Orchid Research Laboratories Limited Heterocycles
PL1973884T3 (pl) * 2006-01-19 2017-05-31 Orchid Pharma Limited Nowe związki heterocykliczne
RU2008140144A (ru) * 2006-03-10 2010-04-20 Оно Фармасьютикал Ко., Лтд. (Jp) Азотосодержащее гетероциклическое производное и фармацевтическое средство, включающее такое производное в качестве активного ингредиента
US20080161324A1 (en) * 2006-09-14 2008-07-03 Johansen Lisa M Compositions and methods for treatment of viral diseases
CN102058885B (zh) 2006-12-22 2013-04-10 瑞蔻达蒂爱尔兰有限公司 采用α2δ配体和NSAID的下泌尿道疾病的联合治疗
CN101626787A (zh) * 2007-01-19 2010-01-13 马林克罗特公司 诊断的和治疗的环氧合酶-2结合配体
WO2008118991A1 (en) 2007-03-26 2008-10-02 University Of Southern California Usc Stevens Methods and compositions for inducing apoptosis by stimulating er stress
JP2010533205A (ja) 2007-07-12 2010-10-21 トラガラ ファーマシューティカルズ，インク． 癌、腫瘍、および腫瘍関連障害を治療するための方法および組成物
AU2009208712B2 (en) 2008-02-01 2013-03-14 Orchid Chemicals & Pharmaceuticals Limited Novel heterocycles
EP2285380A4 (de) * 2008-05-30 2012-03-14 Summa Health Systems Llc Verfahren zur verwendung von tgf-b-rezeptor-hemmern oder der aktivin-like-kinase (alk)-5-hemmer a-83-01 und sb-431542 zur behandlung von augenerkrankungen und wundheilungsleiden
US20100267731A1 (en) * 2009-04-17 2010-10-21 Summa Health Systems, LLC Use of transforming growth factor-b receptor inhibitors to suppress ocular scarring
WO2011038261A1 (en) * 2009-09-24 2011-03-31 Selexagen Therapeutics, Inc. Heterocyclic kinase inhibitors
EP2308866A1 (de) * 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide
TWI532737B (zh) 2010-06-30 2016-05-11 艾諾屋製藥公司 可溶性鳥苷酸環化酶（ｓＧＣ）刺激物
JP5878546B2 (ja) 2010-11-09 2016-03-08 アイアンウッド ファーマシューティカルズ インコーポレイテッド ｓＧＣ刺激剤
CA2861804C (en) 2011-12-27 2021-10-26 Ironwood Pharmaceuticals, Inc. 2-benzyl,3(pyrimidin-2-yl)substituted pyrazoles useful as sgc stimulators
EP3268085A4 (de) 2015-03-13 2018-10-31 The Board of Trustees of The Leland Stanford Junior University Ltb4-hemmung zur vorbeugung und behandlung von lymphödem beim menschen
JP6980534B2 (ja) 2015-06-25 2021-12-15 ザ チルドレンズ メディカル センター コーポレーション 造血幹細胞の増大、富化、および維持に関する方法および組成物
WO2017161001A1 (en) 2016-03-15 2017-09-21 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
WO2018049027A1 (en) 2016-09-07 2018-03-15 Trustees Of Tufts College Combination therapies using immuno-dash inhibitors and pge2 antagonists
CN110963957B (zh) * 2018-09-28 2021-10-22 深圳恩多凯医药科技有限公司 N-芳香酰胺类化合物及其制备方法和用途
US12479816B2 (en) 2019-02-08 2025-11-25 University of Pittsburgh—of the Commonwealth System of Higher Education 20-HETE formation inhibitors
CN113004179B (zh) * 2019-12-20 2022-06-24 江苏中旗科技股份有限公司 一种异噁唑草酮关键中间体的制备方法
IL305573A (en) 2021-03-15 2023-10-01 Saul Yedgar HYALURONIC ACID-CONJUGATED DIPALMITOYL PHOSPHATIDYL ETHANOLAMINE IN COMBINATION WITH NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) FOR TREATING OR ALLEVIATING INFLAMMATORY DISEASES
PL247051B1 (pl) * 2022-11-29 2025-05-05 Univ Medyczny W Lublinie N-podstawione pochodne 1-(1-fenylo-3-arylo)-1H-pirazol-4-ylo) metanaminy, sposób ich wytwarzania i ich zastosowanie

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1261124B (de) * 1961-09-22 1968-02-15 Hoechst Ag Verfahren zur Herstellung von Pyrazolen
US3984431A (en) * 1972-03-15 1976-10-05 Claude Gueremy Derivatives of pyrazole-5-acetic acid
FR2509729A1 (fr) * 1981-07-15 1983-01-21 Pharmindustrie Nouveau procede de preparation de derives du diphenyl-3,4 methyl-5 pyrazole
PH27357A (en) * 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
AU1988692A (en) * 1991-04-24 1992-12-21 E.I. Du Pont De Nemours And Company Fungicidal pyrazoles, pyrazolines and tetrahydropyridazines
US5434178A (en) * 1993-11-30 1995-07-18 G.D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
US5559137A (en) * 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
US5700816A (en) * 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor

Also Published As

Publication number Publication date
JP3490716B2 (ja) 2004-01-26
EP1127878A1 (de) 2001-08-29
EP0772597A1 (de) 1997-05-14
US5756530A (en) 1998-05-26
US6028072A (en) 2000-02-22
DE69524600D1 (de) 2002-01-24
DK0772597T3 (da) 2002-04-08
JPH10503201A (ja) 1998-03-24
AU3126795A (en) 1996-02-22
US5580985A (en) 1996-12-03
PT772597E (pt) 2002-05-31
EP0772597B1 (de) 2001-12-12
US5486534A (en) 1996-01-23
DE69524600T2 (de) 2002-07-18
WO1996003385A1 (en) 1996-02-08
ES2169760T3 (es) 2002-07-16
CA2195123A1 (en) 1996-02-08

Similar Documents

Publication Publication Date Title
DE69524600D1 (de) 3,4-substituierte pyrazole zur behandlung von entzündungen
ATE195118T1 (de) 1,3,5- trisubstituierte pyrazolverbindungen zur behandlung von entzündungen
CA2212836A1 (en) Substituted isoxazoles for the treatment of inflammation
EP1528059A3 (de) Substituierte Isoxazole zur Behandung von Entzündungen
CA2177576A1 (en) Substituted Pyrazolyl Benzenesulfonamides for the Treatment of Inflammation
ATE192436T1 (de) 3,4-diarryl substituierte pyridine zur behandlung von entzündungen
PL1635835T3 (pl) Pochodne 2-aminopirymidyny jako inhibitory kinazy RAF
BR9809451A (pt) Pirazóis substituìdos com 3(5)-heteroarila como inibidores de quinase p38.
HU9503319D0 (en) Phenyl heterocycles as cyclooxygenase-2 inhibitors
IL104311A (en) Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
TW200510334A (en) Preraration and use of aryl alkyl acid derivatives for the treatment of obesity
DK0815087T3 (da) Trisubstituerede phenylderivater
RU2002128916A (ru) Арилзамещенные пиразолы, триазолы или тетразолы (варианты), фармацевтическая композиция, способ лечения заболевания, связанного с блокированием натриевых каналов, у млекопитающего, способ лечения, профилактики или снижения интенсивности различных нарушений или состояний, способ снижения интенсивности или профилактики приступов у животного
ATE224375T1 (de) 4,5-substituierte imidazolylverbindungen zur behandlung von entzundungen
UY23857A1 (es) Procedimiento para la preparación de 1- arilpirazoles substituidos
RU94040154A (ru) Производные фениламиносульфонилмочевины и их соли, гербицидное средство и способы борьбы с сорной растительностью
ATE236130T1 (de) Heterocyclisch substituierte imidazole zur behandlung von entzündungen
CA2559128A1 (en) Kinase inhibitors
WO2000018741A3 (en) Pyrazole compounds as cox-2 inhibitors
DE50001988D1 (de) DOLLAR g(a)- DOLLAR g(a)' -SUBSTITUIERTE N-ALKYL-3-ALKENYLBENZOYL-PYRAZOL-DERIVATE
DK1499312T3 (da) Anvendelse af hydroxypyridonderivater til sårheling
AR011251A1 (es) Metodo de utilizacion de inhibidores de la ciclooxigenasa-2 en el tratamiento y prevencion de neoplasias
WO1999059982A3 (de) Bisoximetherderivate, zwischenprodukte und verwendung zur bekämpfung von schadpilzen und tierischen schädlingen
MY141481A (en) Substituted pyrazoles as p38 kinase inhibitors

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee